TaiMed Biologics (ROCO:4147) Asset Turnover: 0.03 (As of Dec. 2025)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics Asset Turnover?

TaiMed Biologics ROCO:4147 55 Asset Turnover is 0.03 as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued).

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. TaiMed Biologics's Revenue for the three months ended in Dec. 2025 was NT$149.9 Mil. TaiMed Biologics's Total Assets for the quarter that ended in Dec. 2025 was NT$4,814.7 Mil. Therefore, TaiMed Biologics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. TaiMed Biologics's annualized ROE % for the quarter that ended in Dec. 2025 was -7.05%. It is also linked to ROA % through Du Pont Formula. TaiMed Biologics's annualized ROA % for the quarter that ended in Dec. 2025 was -5.69%.


TaiMed Biologics  (ROCO:4147) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

TaiMed Biologics's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-274.152/3889.831
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-274.152 / 599.588)*(599.588 / 4814.7255)*(4814.7255/ 3889.831)
=Net Margin %*Asset Turnover*Equity Multiplier
=-45.72 %*0.1245*1.2378
=ROA %*Equity Multiplier
=-5.69 %*1.2378
=-7.05 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

TaiMed Biologics's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-274.152/4814.7255
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-274.152 / 599.588)*(599.588 / 4814.7255)
=Net Margin %*Asset Turnover
=-45.72 %*0.1245
=-5.69 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


TaiMed Biologics Asset Turnover Related Terms


TaiMed Biologics Asset Turnover Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Asset Turnover Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.13 0.12 0.14 0.13

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.03 0.03 0.03

ROCO:4147 vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, TaiMed Biologics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Asset Turnover falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

TaiMed Biologics's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=611.35/( (4999.247+4810.741)/ 2 )
=611.35/4904.994
=0.12

TaiMed Biologics's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=149.897/( (4818.71+4810.741)/ 2 )
=149.897/4814.7255
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.03 mean?
TaiMed Biologics (ROCO:4147) has a Asset Turnover of 0.03 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on TaiMed Biologics and its competitors.
Is TaiMed Biologics' Asset Turnover too high?
TaiMed Biologics' current Asset Turnover is 0.03. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Asset Turnover compare to VRTX and REGN?
TaiMed Biologics' Asset Turnover of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current Asset Turnover is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Asset Turnover is 0.03. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Asset Turnover is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • Asset Turnover: 0.03
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value